MCID: THR014
MIFTS: 68

Thrombocytopenia

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia

Summaries for Thrombocytopenia

KEGG : 36 Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. Inherited syndromes are relatively rare causes of thrombocytopenia, but some genes underlying these disorders have been elucidated. Some inherited syndromes predispose to the development of bone marrow failure or leukemia. For example, familial platelet disorder with associated myeloid malignancy (FPDMM) is characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.

MalaCards based summary : Thrombocytopenia is related to thrombocytopenia due to platelet alloimmunization and thrombocytopenia 1. An important gene associated with Thrombocytopenia is ANKRD26 (Ankyrin Repeat Domain 26), and among its related pathways/superpathways are Tight junction and Response to elevated platelet cytosolic Ca2+. The drugs Bivalirudin and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cellular

Disease Ontology : 12 A blood platelet disease characterized by low a platelet count in the blood.

PubMed Health : 62 About thrombocytopenia: Thrombocytopenia (THROM-bo-si-to-PE-ne-ah) is a condition in which your blood has a lower than normal number of blood cell fragments called platelets (PLATE-lets). Platelets are made in your bone marrow along with other kinds of blood cells. They travel through your blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes (THROM-bo-sites) because a clot also is called a thrombus.

Wikipedia : 74 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as... more...

Related Diseases for Thrombocytopenia

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1489)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 35.6 MPL ITGB3 ITGA2B ITGA2 GP9 ANKRD26
2 thrombocytopenia 1 35.6 WAS HOXA11 GATA1
3 fetal and neonatal alloimmune thrombocytopenia 35.4 ITGB3 ITGA2B ITGA2 GP1BB GP1BA
4 amegakaryocytic thrombocytopenia, congenital 35.4 RBM8A MPL GATA1
5 acquired thrombocytopenia 35.1 MYH9 MPL ITGB3 IL11 GP1BB
6 thrombocytopenia 2 35.0 MASTL ANKRD26
7 primary thrombocytopenia 35.0 MPL ITGB3 ITGA2B GP1BA ADAMTS13
8 thrombocytopenic purpura, autoimmune 34.8 MPL ITGB3 ITGA2B IL11 GP1BA ADAMTS13
9 myh-9 related disease 34.8 MYH9 MPL GP9 GP1BB GP1BA ANKRD26
10 thrombocytopenia-absent radius syndrome 34.6 RBM8A ANKRD26
11 ankrd26-related thrombocytopenia 34.6 MYH9 ANKRD26
12 autosomal thrombocytopenia with normal platelets 34.5 MASTL CYCS
13 bernard-soulier syndrome 34.5 MYH9 ITGB3 ITGA2B ITGA2 GP9 GP1BB
14 platelet disorder, familial, with associated myeloid malignancy 34.2 RUNX1 ETV6 ANKRD26
15 blood platelet disease 33.8 WAS RUNX1 MYH9 MPL ITGB3 ITGA2B
16 gray platelet syndrome 33.6 MASTL ITGA2B GP9 GATA1
17 pseudo-von willebrand disease 33.5 GP9 GP1BB GP1BA GATA1
18 purpura 33.0 MPL ITGB3 ITGA2B GP1BA ADAMTS13
19 thrombosis 32.6 MPL ITGB3 ITGA2B ITGA2 GP1BA ADAMTS13
20 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 32.5 RUNX1 ETV6
21 autosomal dominant macrothrombocytopenia 32.5 MYH9 ITGB3 ITGA2B GP1BB GP1BA ACTN1
22 myelodysplastic syndrome 32.4 RUNX1 MPL ITGA2B IL11 GATA1 ETV6
23 deficiency anemia 32.4 MPL IL11 GP1BA GATA1 ADAMTS13
24 aplastic anemia 32.1 MPL ITGB3 ITGA2B IL11 GATA1
25 leukemia, acute myeloid 32.0 RUNX1 MPL ITGB3 ITGA2B GATA1 ETV6
26 von willebrand's disease 32.0 ITGB3 ITGA2 GP9 GP1BA ADAMTS13
27 bleeding disorder, platelet-type, 16 32.0 ITGB3 ITGA2B
28 essential thrombocythemia 31.8 MPL ITGB3 ITGA2B IL11 GP1BA GATA1
29 myelofibrosis 31.8 RUNX1 MPL GATA1 ETV6
30 thrombasthenia 31.7 ITGB3 ITGA2B ITGA2 GP9 GP1BA
31 splenic sequestration 31.7 MPL ITGA2B ADAMTS13
32 leukemia, chronic myeloid 31.5 RUNX1 MPL ITGB3 IL11 GATA1 ETV6
33 myeloproliferative neoplasm 31.5 RUNX1 MPL ITGB3 GATA1 ETV6
34 cerebrovascular disease 31.5 ITGB3 ITGA2B ITGA2 GP1BA ADAMTS13
35 glanzmann thrombasthenia 31.5 ITGB3 ITGA2B ITGA2 GP9 GP1BA
36 myocardial infarction 31.4 ITGB3 ITGA2B ITGA2 GP1BA CYCS ADAMTS13
37 coronary thrombosis 31.3 ITGB3 ITGA2B GP1BA
38 megakaryocytic leukemia 30.9 RUNX1 ITGB3 ITGA2B IL11 GATA1
39 refractory anemia 30.9 RUNX1 MPL
40 chronic myelomonocytic leukemia 30.9 RUNX1 MPL ETV6
41 hematologic cancer 30.8 RUNX1 MPL IL11 ETV6 CYCS
42 qualitative platelet defect 30.8 ITGA2B GP1BA
43 velocardiofacial syndrome 30.5 GP9 GP1BB GP1BA
44 aspirin resistance 30.5 ITGB3 ITGA2
45 arteritic anterior ischemic optic neuropathy 30.4 ITGB3 GP1BA
46 heparin-induced thrombocytopenia 12.7
47 thrombocytopenia with beta-thalassemia, x-linked 12.7
48 thrombocytopenia, paris-trousseau type 12.6
49 dyserythropoietic anemia and thrombocytopenia 12.6
50 thrombocytopenia, x-linked, with or without dyserythropoietic anemia 12.6

Graphical network of the top 20 diseases related to Thrombocytopenia:



Diseases related to Thrombocytopenia

Symptoms & Phenotypes for Thrombocytopenia

GenomeRNAi Phenotypes related to Thrombocytopenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ETV6 GATA1 GP1BA ITGA2 ITGA2B RBM8A

MGI Mouse Phenotypes related to Thrombocytopenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 CYCS ETV6 GATA1 GP1BA HOXA11 ITGA2
2 hematopoietic system MP:0005397 10 ADAMTS13 CYCS ETV6 GATA1 GP1BA GP1BB
3 embryo MP:0005380 9.91 CYCS ETV6 GATA1 ITGA2B ITGB3 MASTL
4 homeostasis/metabolism MP:0005376 9.77 ADAMTS13 ANKRD26 ETV6 GATA1 GP1BA GP1BB
5 immune system MP:0005387 9.36 ADAMTS13 CYCS ETV6 GATA1 GP1BB ITGA2B

Drugs & Therapeutics for Thrombocytopenia

PubMed Health treatment related to Thrombocytopenia: 62

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding . If your condition is mild, you may not need treatment . A fully normal platelet count isn't necessary to prevent bleeding , even with severe cuts or accidents. Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition usually don't need treatment . If a reaction to a medicine is causing a low platelet count, your doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin -induced thrombocytopenia (HIT), stopping the heparin isn't enough. Often, you'll need another medicine to prevent blood clotting . If your immune system is causing a low platelet count, your doctor may prescribe medicines to suppress the immune system.

Drugs for Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 544)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Phylloquinone Approved, Investigational Phase 4 84-80-0
15
Abciximab Approved Phase 4 143653-53-6
16
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
17
Cefpirome Approved Phase 4 84957-29-9 5479539
18
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
19
Tirofiban Approved Phase 4 144494-65-5 60947
20 Bemiparin Approved, Investigational Phase 4 91449-79-5
21
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
22
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
23
Pancrelipase Approved, Investigational Phase 4 53608-75-6
24
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
25
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
26
Ethanol Approved Phase 4 64-17-5 702
27
Azithromycin Approved Phase 4 83905-01-5 447043 55185
28
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
29
Lorazepam Approved Phase 4 846-49-1 3958
30
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
31
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
32
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
33
tannic acid Approved Phase 4 1401-55-4
34
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
35
Dalteparin Approved Phase 4 9005-49-6
36
Clarithromycin Approved Phase 4 81103-11-9 84029
37
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
38
Enoxaparin Approved Phase 4 9005-49-6 772
39
Warfarin Approved Phase 4 81-81-2 6691 54678486
40
Desirudin Approved Phase 4 120993-53-5
41
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
42
Ribavirin Approved Phase 4 36791-04-5 37542
43
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
44
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
45
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
46
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
47
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
48
Mycophenolic acid Approved Phase 4 24280-93-1 446541
49
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
50
Tenecteplase Approved Phase 4 191588-94-0

Interventional clinical trials:

(show top 50) (show all 1042)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
3 Randomized Double Blind Trial Comparing Heparin and Placebo as Additives to Continuous Infusion in Intensive Care Neonates for Prevention of Ventilation Unknown status NCT00196469 Phase 4 heparin
4 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients Unknown status NCT02355873 Phase 4
6 A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention Unknown status NCT00407771 Phase 4 Tirofiban
7 Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy Unknown status NCT00999258 Phase 4 sirolimus
8 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
9 Bivalirudin PCI Registry in HIT/HITTS Patients Completed NCT00759083 Phase 4 bivalirudin
10 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
11 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
12 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
13 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
14 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
15 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
16 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
17 Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE) Completed NCT00913133 Phase 4 Desirudin
18 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
19 Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Completed NCT01789762 Phase 4
20 Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial Completed NCT01269112 Phase 4
21 Bicentric Clinical Trial With in Vitro Experiments to Assess the Effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
22 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
23 A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
24 International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings Completed NCT00622648 Phase 4 Enoxaparin;Placebo
25 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
26 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
27 Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3 Completed NCT00262054 Phase 4 Bivalirudin;Un-fractionated heparin
28 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
29 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
30 Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions Completed NCT00448461 Phase 4 heparin;bivalirudin
31 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
32 FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study Completed NCT00383136 Phase 4 tirofiban high-bolus dose regimen;Abciximab
33 Efficacy of Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial Completed NCT03333395 Phase 4 Nebulized heparin and salbutamol;Nebulized salbutamol
34 A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting Completed NCT00169819 Phase 4 Abciximab
35 Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand Completed NCT02247440 Phase 4 Peg-interferon + ribavirin under HIV physician supervision
36 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
37 Facilitation Through Abciximab By drOpping Infusion Line in Patients Undergoing Coronary Stenting. SYNergy With Clopidogrel at High Loading dOse Regimen Completed NCT00929279 Phase 4 bolus+infusion;abciximab bolus only regimen
38 Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial) Completed NCT02563041 Phase 4 30% TSC;Heparin
39 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
40 The Effect of Prasugrel as Compared to Clopidogrel on Platelet Function Immediately Following the Termination of Intravenous Bivalirudin in Patients Undergoing Percutaneous Coronary and Structural Cardiac Intervention Completed NCT01789814 Phase 4 Prasugrel;Clopidogrel
41 Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries: a Double Blind, Placebo-controlled Study Completed NCT03664037 Phase 4 Dexamethasone phosphate;Placebo
42 Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy Completed NCT00188955 Phase 4 sirolimus
43 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
44 Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study Completed NCT03146858 Phase 4 Enoxaparin
45 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
46 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
47 Venous Thromboembolism Prevention in the Morbidly Obese Medically Ill Patient: A Pharmacological Analysis of the Predictability of Prophylactic Weight-Based Enoxaparin Dosing. Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
48 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
49 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
50 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4

Search NIH Clinical Center for Thrombocytopenia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Thrombocytopenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: thrombocytopenia

Genetic Tests for Thrombocytopenia

Genetic tests related to Thrombocytopenia:

# Genetic test Affiliating Genes
1 Thrombocytopenia 29

Anatomical Context for Thrombocytopenia

MalaCards organs/tissues related to Thrombocytopenia:

40
Liver, Bone, Bone Marrow, Lung, Myeloid, Breast, Testes

Publications for Thrombocytopenia

Articles related to Thrombocytopenia:

(show top 50) (show all 30373)
# Title Authors PMID Year
1
Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats. 54 61
19705256 2010
2
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 61 54
20175767 2010
3
Agranulocytosis in dengue hemorrhagic fever: a neglected condition. 54 61
20462096 2010
4
Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. 54 61
20430179 2010
5
The prothrombotic potential of platelet factor 4. 54 61
20206875 2010
6
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 54 61
20181616 2010
7
Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. 61 54
20154285 2010
8
Proteinase-activated receptor (PAR1) polymorphic variant correlates with thrombocytopenia in Gaucher disease. 61 54
19969492 2010
9
Serum thrombopoietin level and thrombocytopenia during the neonatal period in infants with Down's syndrome. 61 54
19675574 2010
10
A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers. 54 61
19740526 2010
11
A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13. 61 54
20121555 2010
12
Heparin-induced thrombocytopenia. 54 61
20059332 2010
13
Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. 54 61
19451811 2010
14
Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. 61 54
19709391 2010
15
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 54 61
20203368 2010
16
Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. 61 54
19679353 2010
17
Infectious causes of chronic immune thrombocytopenia. 54 61
19932434 2009
18
Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery. 61 54
19783545 2009
19
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 54 61
19409826 2009
20
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. 61 54
19671919 2009
21
Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding. 54 61
19815879 2009
22
Intracranial hemorrhage in dengue fever: management and outcome: a series of 5 cases and review of literature. 61 54
19328535 2009
23
[Two Crimean-Congo hemorrhagic fever cases without history of tick contact from Ankara region]. 61 54
20084924 2009
24
Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. 61 54
19337732 2009
25
Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. 61 54
19118853 2009
26
Buerger's disease and anticardiolipin antibodies. 61 54
19455050 2009
27
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. 61 54
19698012 2009
28
Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies. 61 54
19497062 2009
29
Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. 54 61
19801810 2009
30
Thrombopoietin receptor agonists in the treatment of thrombocytopenia. 54 61
19553811 2009
31
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. 54 61
19628164 2009
32
Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. 54 61
19473438 2009
33
[Catastrophic antiphospholipid syndrome complicated by cardiogenic shock - a case report]. 54 61
19650000 2009
34
Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. 54 61
19572073 2009
35
Patterns of acquired bleeding disorders in a tertiary care hospital. 54 61
19520680 2009
36
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. 61 54
19195684 2009
37
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 61 54
19200137 2009
38
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. 61 54
19351959 2009
39
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 54 61
19252138 2009
40
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 54 61
19207581 2009
41
Identification of a predictive biomarker for hematologic toxicities of gemcitabine. 54 61
19289617 2009
42
Eosinophilic enteritis in association with systemic lupus erythematosus. 54 61
19318400 2009
43
Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. 54 61
19302922 2009
44
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 54 61
19037596 2009
45
An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. 54 61
19452409 2009
46
Clinical implications of alpha-fetoprotein in chronic hepatitis C. 54 61
19293036 2009
47
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. 61 54
19055667 2009
48
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. 61 54
19270304 2009
49
Severe vitamin B-12 deficiency in a child mimicking thrombotic thrombocytopenic purpura. 54 61
18985742 2009
50
Prevalence of heparin-induced antibody in African-American hemodialysis patients--comparison to non-dialysis patients. 61 54
19281736 2009